维奈克拉-利妥昔单抗固定疗程治疗复发/难治性慢性淋巴细胞白血病可清除微小残留病灶并延长生存:MURANO III期研究治疗后随访
MURANO研究显示,复发/难治性慢性淋巴细胞白血病患者接受固定疗程维奈克拉-利妥昔单抗较苯达莫司汀-利妥昔单抗显著改善无进展生存期。所有患者完成治疗后,外周血微小残留病灶(MRD)清除率在联合治疗结束时为62% vs 13%,且uMRD状态可预测更长的PFS。中位随访36个月,PFS和OS仍优于对照组。
要点
- 固定疗程维奈克拉-利妥昔单抗较苯达莫司汀-利妥昔单抗显著改善PFS(HR 0.16)和OS(HR 0.50)。
- 联合治疗结束时外周血uMRD率62% vs 13%,优势持续至第24个月。
- uMRD状态可预测更长PFS,低水平MRD较高水平MRD预测更好PFS。
核心结论
- 所有患者完成治疗后,维奈克拉-利妥昔单抗较苯达莫司汀-利妥昔单抗持续显示获益。
- uMRD率持久且可预测更长PFS,确立了外周血MRD对含维奈克拉固定疗程治疗获益的影响。
- 完成2年维奈克拉-利妥昔单抗后低转化至可检测MRD和持续PFS证明该方案的可行性。
研究设计与样本
- MURANO为III期随机对照研究,患者随机分配至2年维奈克拉联合前6周期利妥昔单抗组或6周期苯达莫司汀-利妥昔单抗组。
- 共194例患者,174例(90%)完成维奈克拉-利妥昔单抗阶段,130例(67%)完成2年维奈克拉治疗。
- 主要终点为PFS,次要终点包括安全性和外周血MRD状态(第4周期、联合治疗结束后2-3个月及之后每3-6个月)。
主要发现
- 中位随访36个月,维奈克拉-利妥昔单抗组PFS仍优于苯达莫司汀-利妥昔单抗组(HR 0.16,95%CI 0.12-0.23)。
- 中位随访36个月,维奈克拉-利妥昔单抗组OS仍优于苯达莫司汀-利妥昔单抗组(HR 0.50,95%CI 0.30-0.85)。
- 联合治疗结束时外周血uMRD(<10^-4)率维奈克拉-利妥昔单抗组62% vs 苯达莫司汀-利妥昔单抗组13%,优势持续至第24个月(治疗结束)。
- 联合治疗结束时uMRD状态预测更长PFS;可检测MRD患者中,低水平MRD(10^-4至<10^-2)较高水平MRD(≥10^-2)预测改善的PFS。
- 完成固定疗程维奈克拉-利妥昔单抗后中位9.9个月(范围1.4-22.5个月),总体仅12%(16/130)患者出现疾病进展(11例高水平MRD,3例低水平MRD)。
关键数值与推荐
- 外周血uMRD定义为MRD <10^-4。
- 低水平MRD定义为10^-4至<10^-2;高水平MRD定义为≥10^-2。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia. With all patients off treatment, we report minimal residual disease (MRD) kinetics and updated outcomes. METHODS: Patients were randomly assigned to 2 years of venetoclax plus rituximab during the first six cycles, or six cycles of bendamustine-rituximab. Primary end point was PFS. Safety and peripheral blood (PB) MRD status-at cycle 4, 2 to 3 months after end of combination therapy (EOCT), and every 3 to 6 months thereafter-were secondary end points. RESULTS: Of 194 patients, 174 (90%) completed the venetoclax-rituximab phase and 130 (67%) completed 2 years of venetoclax. With a median follow-up of 36 months, PFS and overall survival remain superior to bendamustine-rituximab (hazard ratio, 0.16 [95% CI, 0.12 to 0.23]; and hazard ratio, 0.50 [95% CI, 0.30 to 0.85], respectively). Patients who received venetoclax-rituximab achieved a higher rate of PB undetectable MRD (uMRD; less than 10-4) at EOCT (62% v 13%) with superiority sustained through month 24 (end of therapy). Overall, uMRD status at EOCT predicted longer PFS. Among those with detectable MRD, low-level MRD (10-4 to less than 10-2) predicted improved PFS compared with high-level MRD (10-2 or greater). At a median of 9.9 months (range, 1.4 to 22.5 months) after completing fixed-duration venetoclax-rituximab, overall only 12% (16 of 130) of patients developed disease progression (11 high-level MRD, three low-level MRD). At the end of therapy, 70% and 98% of patients with uMRD remained in uMRD and without disease progression, respectively. CONCLUSION: With all patients having finished treatment, continued benefit was observed for venetoclax-rituximab compared with bendamustine-rituximab. uMRD rates were durable and predicted longer PFS, which establishes the impact of PB MRD on the benefit of fixed-duration, venetoclax-containing treatment. Low conversion to detectable MRD and sustained PFS after completion of 2 years of venetoclax-rituximab demonstrate the feasibility of this regimen.
引用
- Kater AP, Seymour JF, Hillmen P, et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2018. PMID: 30523712. doi:10.1200/JCO.18.01580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。